Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0E4GE
|
|||
| Former ID |
DIB008826
|
|||
| Drug Name |
AZD-2551
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Protease unspecific (PRO) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00860353) Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses ofAZD2551. U.S. National Institutes of Health. | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800029854) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.